Skip to content

Systematic Review of published reports of Clinical Trials for comparison of effectiveness of different doses of Vitamin D used in treatment of potentially deadly diseases

A Systematic Review of Clinical Trials on Comparative Effectiveness of Vitamin D Dosages on varied Outcomes- The Ultimate Guide exploring Extra- Nutritional Role of Vitamin D - Nill

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/09/094241
Enrollment
Unknown
Registered
2025-09-04
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E559- Vitamin D deficiency, unspecified

Interventions

Intervention1: Vitamin D3: The total duration of the systematic review is intended to be six months from the day of ethics committee approval All available pharmaceutical preparations not restricted 1

Sponsors

Shakeeb S Dhorajiwala
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Study design Systematic review Randomized controlled Clinical trials published trial reports

Exclusion criteria

Exclusion criteria: 1. Studies not published in English 2. Studies with insufficient data for analysis. 3. Studies not published 4. Paid access to publication

Design outcomes

Primary

MeasureTime frame
1 All cause mortality 2 Cardiovascular events 3 Cancer outcome 4 Inflammatory conditions 5 Respiratory Outcomes Timepoint: all outcomes will be subjected to metanalysis within six months

Secondary

MeasureTime frame
1.Other Health Conditions: 1.1 Cognitive function (e.g., executive function) 1.2 Functional outcomes 1.3 Wellbeing 1.4 Risk of infection (any, bacterial vaginosis) 1.5 Tuberculosis cure rate 1.6 Sputum smear or culture positivity in tuberculosis patients 1.7 CD4 cell count in HIV patients with tuberculosis 2.Adverse Events: 2.1 Renal stone formation 2.2 Elevated blood levels of calcium (hypercalcemia) 2.3 Hypercalciuria 2.4 Vomiting (in COVID-19 patients) 2.5 Serious adverse eventsTimepoint: all secondary outcomes will be subjected to metanalysis within six months

Countries

India

Contacts

Public ContactShakeeb Siraj Dhorajiwala

Seth GSMC and Kem hospital

shakeebdhorajiwala@kem.edu7709795204

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 23, 2026